CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia inducible factor (HIF), today
announced that John P. Butler, President and Chief Executive Officer,
will present at the Oppenheimer 25th Annual Healthcare Conference onThursday, December 11,2014 at 1:00 p.m. Eastern Time. The
conference will take place at Crowne Plaza Times Square Manhattan in New
York City.
A live audio webcast of the presentations will be available on the
company's website at http://ir.akebia.com/events.cfm.
An archived presentation will be available for 90 days.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through HIF biology. Akebia's lead
product candidate, AKB-6548, is a once-daily, oral therapy, which has
completed a Phase 2b study for the treatment of anemia related to CKD in
non-dialysis patients and is in a Phase 2 study for the treatment of
anemia in patients undergoing dialysis. For more information on Akebia,
please visit www.akebia.com.
Investors:
Akebia Therapeutics, Inc.
Nicole P. Jones,
+1-617-871-1210
Senior Director, Investor Relations and Corporate
Communications
njones@akebia.com
or
Media:
Argot
Partners
Eliza Schleifstein, +1-917-763-8106
Eliza@argotpartners.com
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media